NewsRelease

ResearchArticle Cites HemoVoid™ in Biomarker Study for Obstructive SleepApnea

MONMOUTHJUNCTION, NJ, December3,2020 -- Biotech Support Group reports on a recent research articledescribing the simplicity and efficiency of their hemoglobindepletion technology to observe and report the redblood cell (RBC) proteome by two dimensional difference gelelectrophoresis (2D-DIGE)in ObstructiveSleep Apnea (OSA).

Thecitation is:

Valentim-Coelho,Cristina, et al. "Redox–OligomericState of Peroxiredoxin-2 and Glyceraldehyde-3-Phosphate Dehydrogenasein Obstructive Sleep Apnea Red Blood Cells under Positive AirwayPressure Therapy." Antioxidants 9.12(2020): 1184.

Inthis study, the authors examined the effect of six months of positiveairway pressure (PAP) therapy on patients with Obstructive SleepApnea (OSA). The red blood cell (RBC) proteome was analyzed by twodimensional difference gel electrophoresis (2D-DIGE) - basedproteomics followed by Western blotting (WB) validation. Inthe DiscoveryPhase, for 2D-DIGE Proteomics, the article states “RBC samples(Cohort I) were lysed by incubation with 5 mM phosphate buffer pH 7.4(1:20) containing 1:100 cocktail of protease inhibitors … for 30min at 4◦C followed sonication…. After centrifugation …, thesupernatants were recovered for further hemoglobin (Hb) depletionusing HemoVoid™ depletion columns (Biotech Support Group, MonmouthJCT, NJ, USA), according to the manufacture’s protocol.” Theresults indicated that the redox–oligomeric state of GAPDH andPRDX2 involving overoxidation by sulfinic/sulfonic acids weredifferentially modulated in OSA RBC, which might be compromising RBChomeostasis. Therefore, information on the redox status of PRDX2 andGAPDH in RBC will help to better recognize OSA subtypes and predictthe therapeutic response to positive airway pressure (PAP) therapy inthese patients. 

“Wehave focused our development efforts around proteomic profiling ofthe various blood compartments. I am very pleased to see anotherarticle illustrating the ability to enrich for the underlyingsub-proteome from the cytosolic fraction of red cells as a uniquefeature of HemoVoid™. That two differentially expressed proteinswere identified in this study, demonstrates its flexibility for awide variety of applications”, states Swapan Roy, Ph.D., Presidentand Founder of Biotech Support Group.

Formore information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

Formore information oo all of BSG’s Hemoglobin removal products,visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal.From these innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go to  http://www.biotechsupportgroup.com.

ForBusiness Development, contact:

MatthewKuruc 732-274-2866, [email protected]